Identification of non-functional allelic variant of CYP1A2 in dogs

Pharmacogenetics

Volumn 14, Issue 11, 2004, Pages 769-773

  Mise, Masashi ^a   Hashizume, Takanori ^a   Matsumoto, Satoshi ^a   Terauchi, Yoshiaki ^a   Fujii, Toshihiko ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

CYP1A2; Dog; PCR RFLP; Single nucleotide polymorphism

Indexed keywords

5 (3 METHOXYPHENYL) 3 (5 METHYL 1,2,4 OXADIAZOL 3 YL) 2 OXO 1,2 DIHYDRO 1,6 NAPHTHYRIDINE; CYTOCHROME P450 1A2; HEME; NAPHTHYRIDINE DERIVATIVE; RADEQUINIL; UNCLASSIFIED DRUG;

ALLELE; ALLELIC EXCLUSION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BREED DIFFERENCE; CONTROLLED STUDY; CYP1A2 GENE; DOG; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; FREQUENCY ANALYZER; GENE; GENE SEQUENCE; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; MALE; MISMATCH NEGATIVITY; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PHARMACOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICOLOGY;

ALLELES; ANIMALS; BASE SEQUENCE; CYTOCHROME P-450 CYP1A2; DNA PRIMERS; DNA, COMPLEMENTARY; DOGS; GENOTYPE; LIVER; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

CANIS FAMILIARIS;

EID: 9244232287     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200411000-00008     Document Type: Article

References (24)

1. Nunoya KI, Yokoi T, Kimura K, Kainuma T, Satoh K, Kinoshita M, et al. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther 1999; 289:437-442.
2. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-349.
3. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269:15419-15422.
4. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990; 265:17209-17214.
5. Pelkonen O, Boobis AR, Kremers P, Ingelman-Sundberg M, Rane A. Interindividual variation of P450 enzymes in vitro and its causes. In: Pacifici GM, Pelkonen O, editors. Interindividual Variability in Human Drug Metabolism. London: Taylor & Francis; 2001. pp. 269-332.
6. Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, et al. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 1999; 27:1133-1142.
7. Blaisdell J, Goldstein JA, Bai SA. Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 1998; 26:278-283.
8. Roussel F, Duignan DB, Lawton MP, Obach RS, Strick CA, Tweedie DJ. Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys 1998; 357:27-36.
9. Lankford SM, Bai SA, Goldstein JA. Cloning of canine cytochrome P450 2E1 cDNA: identification and characterization of two variant alleles. Drug Metab Dispos 2000; 28:981-986.
10. Mise M, Yadera S, Matsuda M, Hashizume T, Matsumoto S, Terauchi Y, et al. Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab Dispos 2004; 32:240-245.
11. Uchida T, Komori M, Kitada M, Kamataki T. Isolation of cDNAs coding for three different forms of liver microsomal cytochrome P-450 from polychlorinated biphenyl-treated beagle dogs. Mol Pharmacol 1990; 38:644-651.
12. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol 1989; 3:1399-1408.
13. Landi MT, Sinha R, Lang NP, Kadlubar FF. Human cytochrome P4501A2. IARC Sci Publ 1999:173-195.
14. Graham RA, Downey A, Mudra D, Krueger L, Carroll K, Chengelis C, et al. In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metab Dispos 2002; 30:1206-1213.
15. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29:413-580.
16. Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV, Gonzalez FJ. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 1990; 126:3101-3106.
17. Kerlan V, Dreano Y, Bercovici JP, Beaune PH, Floch HH, Berthou F. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochem Pharmacol 1992; 44:1745-1756.
18. Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 1998; 11:659-665.
19. von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Rojdmark S. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 2000; 56:123-127.
20. Facciola G, Hidestrand M, von Bahr C, Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 2001; 56:881-888.
21. Pineau T, Fernandez-Salguero P, Lee SS, McPhail T, Ward JM, Gonzalez FJ. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci U S A 1995; 92:5134-5138.
22. Liang HC, Li H, McKinnon RA, Duffy JJ, Potter SS, Puga A, et al. Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism. Proc Natl Acad Sci U S A 1996; 93:1671-1676.
23. Smith AG, Davies R, Dalton TP, Miller ML, Judah D, Riley J, et al. Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics 2003; 111:45-51.
24. Allorge D, Chevalier D, Lo-Guidice JM, Cauffiez C, Suard F, Baumann P, et al. Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 2003; 56:341-344.